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Abstract  
Loss of 3p11-p14 is a frequent event in epithelial cancer and a candidate prognostic 
biomarker in cervical cancer. In addition to loss, promoter methylation can participate in gene 
silencing and promote tumor aggressiveness. We have performed a complete mapping of 
promoter methylation at 3p11-p14 in two independent cohorts of cervical cancer patients 
(n=149, n=121), using Illumina 450K methylation arrays. The aim was to investigate whether 
hypermethylation was frequent and could contribute to gene silencing and disease 
aggressiveness either alone or combined with loss. By comparing the methylation level of 
individual CpG sites with corresponding data of normal cervical tissue, 26 out of 41 genes 
were found to be hypermethylated in both cohorts. The frequency of patients with 
hypermethylation of these genes was found to be higher at tumor stages of 3 and 4 than in 
stage 1 tumors. Seventeen of the 26 genes were transcriptionally downregulated in cancer 
compared to normal tissue, whereof six genes showed a significant correlation between 
methylation and expression. Integrated analysis of methylation, gene dosage, and expression 
of the 26 hypermethylated genes identified three regulation patterns encompassing eight 
hypermethylated genes; a methylation driven pattern (C3orf14, GPR27, ZNF717), a gene 
dosage driven pattern (THOC7, PSMD6), and a combined methylation and gene dosage 
driven pattern (FHIT, ADAMTS9, LRIG1). In survival analysis, patients with both 
hypermethylation and loss of LRIG1 had a worse outcome compared to those harboring only 
hypermethylation or none of the events. C3orf14 emerged as a novel methylation regulated 
suppressor gene, for which knockdown was found to promote invasive growth in human 
papilloma virus (HPV)-transformed keratinocytes. In conclusion, hypermethylation at 3p11-
p14 is common in cervical cancer and may exert a selection pressure during carcinogenesis 
alone or combined with loss. Information on both events could lead to improved prognostic 
markers.   
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Introduction  
Chromosomal loss and hypermethylation of CpG sites in promoter regions are major 
mechanisms of gene silencing in cancer 1-3. Strong evidences for an important role of both 
events in the carcinogenesis of cervical cancer have been presented 4-8. A connection between 
the two events has been hypothesized and was recently supported by a genome wide study in 
breast cancer, showing significant enrichment of differentially methylated regions at 
chromosomal breakpoints like fragile sites 9. Hence, promoter methylation may cooperate 
with loss in gene silencing and possibly enhance the malignant phenotype associated with the 
chromosomal aberration or promote chromosomal instability and loss of the unaffected allele 
10,11
. This has been demonstrated in experimental studies where loss of gene function was 
associated with hypermethylation of one allele coupled with mutation of the other allele 12,13. 
Promoter methylation and loss may also be alternative routes towards increased malignancy 
where gene silencing is caused by methylation in some tumors or tumor clones and loss in 
others. To fully understand how the two events contribute in the carcinogenesis of cervical 
cancer, their possible individual and combined effects on gene silencing must be clarified.  
 
Loss on chromosome 3p encompassing the fragile site FRA3B at p14.2 is a frequent event in 
many epithelial cancers and a candidate prognostic biomarker of cervical cancer 5,14,15. These 
findings indicate an important role of the loss in cancer development, and efforts have been 
undertaken to understand its biological meaning. In cervical cancer, the loss seems to 
constitute a selection advantage early in the invasive phase of the disease, promoting a 
treatment resistant phenotype 16. By a complete transcript mapping of the prognostic 3p11.2-
p14.2 region, we have identified eight candidate targets of the loss; THOC7, PSMD6, 
SLC25A26, TMF1, RYBP, SHQ1, EBLN2, and GBE1, for which silencing was associated with 
activation of tumorigenic pathways in proliferation and anti-apoptosis 16. However, the region 
harbors other potential suppressor genes, like ROBO1, FHIT, and FAM19A4, which might 
primarily be regulated by methylation 17-19. More comprehensive studies, integrating promoter 
methylation and chromosomal loss of the entire prognostic region, would reveal a possible 
interplay between the two events in gene silencing and thereby provide a better understanding 
of the aggressive phenotype predicted by the loss. 
  
In the present study we have performed a complete mapping of promoter methylation at 
3p11.2-p14.2 in cervical cancer using the Illumina 450K methylation arrays, which detect the 
methylation level of more than 485 000 CpG sites and cover 96% of CpG islands and 99% of 
all genes in the RefSeq database 20. The aim was to investigate whether hypermethylation was 
a frequent event and could contribute to gene silencing and disease aggressiveness, either 
alone or in combination with loss. The methylation data was found to be highly consistent at 
the level of individual CpG sites in two independent patient cohorts, demonstrating 
considerable robustness in the technology. Hypermethylated sites were identified by 
comparing the methylation level to the corresponding level in normal cervical tissue. The 
methylation data were further integrated with gene dosage and expression data. This approach 
proposed individual as well as combined effects of methylation and loss on gene silencing and 
suggested that the regulation pattern could influence the aggressive phenotype of the disease. 
Moreover, a novel methylation regulated suppressor candidate was discovered, for which 
downregulation was shown to promote invasive growth in human papilloma virus (HPV)-
transformed keratinocytes. 
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Results  
Hypermethylated CpG sites on 3p gene promoters  
Based on an investigation cohort of 149 patients (cohort 1; Table S1), 559 CpG sites were 
mapped to the promoter region of 48 genes at 3p11.2-p14.2. After data preprocessing, 
including exclusion of sites with low variation in their β-value across the samples, 229 CpGs 
on 41 genes remained. To identify hypermethylated sites that were differentially methylated 
between normal and tumor samples, the β-value of each site and tumor was compared to the 
β-distribution of the corresponding site in an external methylation data set of 20 normal 
cervical samples (GSE46306). A CpG site of a tumor sample was defined as hypermethylated 
if β exceeded the median plus two times the standard deviation of the corresponding site in 
the normal samples. This resulted in 150 CpGs on 26 genes which were hypermethylated in at 
least 10% of the patients (Fig. 1). Frequency of chromosomal loss on the same region ranged 
from 55% to 60% (Fig. 1). When stratifying the patients based on FIGO stage, a gradual 
increase in the average hypermethylation frequency of the 26 genes with increasing stage, 
which reached statistical significance when comparing stage 1 and stage 3/4 tumors, was seen 
(p = 0.04; Fig. S1). For chromosomal loss, the frequency was higher for stage 1 compared to 
stage 2, 3, and 4 (p < 0.001).  
 
The number of hypermethylated sites differed considerably among the 26 genes, ranging from 
a single to 17 CpGs. To ensure reliability in our results, we performed a probe based 
validation in an independent cohort of 121 patients (cohort 2; Table S1). All 150 sites were 
found to be hypermethylated in at least 4 patients (3.3%) in cohort 2 and a highly significant 
correlation was found between the hypermethylation frequencies of individual CpG sites in 
the two cohorts (Fig. 2; Table S2). This supports the findings in Figure 1 and indicates that 
the observed frequencies are characteristic of cervical cancer. The 26 genes were candidates 
for methylation controlled silencing and were selected for the further analyses (Table 1). 
Silencing of hypermethylated genes 
Relationships between hypermethylation and silencing of the genes were investigated by 
analyzing their expression in normal tissues and cancer. First, the expression was compared 
between tumors and normal cervical samples in three external datasets (GSE6791, GSE7803, 
GSE9750). Totally 17 genes had a mean expression that was lower in tumors than in normal 
tissues and significantly downregulated at an adjusted (adj) p ≤ 0.10 in at least one of the 
datasets (Fig. 3A). The downregulated genes included many of the most frequently 
hypermethylated genes from Figure 1, showing a hypermethylation frequency in the range 
from 16.6 to 89.3 in cohort 1 (Table 1).   
 
Second, a possible correlation between methylation and expression was investigated in our 
tumor data sets. In cohort 1, eight genes showed a highly significant negative correlation 
between the β-value of at least one CpG site and expression (adj p ≤ 0.10; Fig. 3B). For 
LRIG1, PSMD6, and ROBO2, significant correlation was found for the only CpG, whereas the 
others had two (FHIT, GPR27, ZNF717), seven (PDZRN3), and 11 (C3orf14) significant 
CpGs (Fig. 3C; Table S2). The reproducibility of the results was investigated in cohort 2, 
where the expression data were based on another Illumina beadarray version. A similar 
correlation was found for all but nine sites, using the same strict significance level and the 
same expression probe in cases of several probes representing the same gene (Fig. 3C). The 
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six most significant genes in cohort 1 had at least one significant CpG in both cohorts, and for 
C3orf14, the correlation was confirmed for nine CpGs, suggesting a high degree of 
reproducibility across patient cohorts. All together, these analyses indicate a relationship 
between promoter hypermethylation and silencing of specific genes within the region.  
 
Combined effect of hypermethylation and loss on gene expression  
To investigate a possible combined effect of hypermethylation and loss on the expression of 
the hypermethylated genes in Table 1, we divided 73 tumors with pairwise methylation, gene 
dosage, and expression data into four groups with different combinations of gene dosage 
(loss, no loss) and methylation status (hypermethylated, not hypermethylated) and performed 
a systematic comparison of the expression between the groups. By claiming an adjusted p ≤ 
0.10, three different gene regulation patterns involving eight genes were suggested; 
methylation driven regulation, gene dosage driven regulation, and combined methylation and 
gene dosage driven regulation (Table 1). In the methylation driven pattern, only 
hypermethylation, and not loss, was associated with downregulation. This pattern was seen 
for C3orf14, where downregulation by methylation was found in both the loss and no loss 
group, and for GPR27 and ZNF717, where downregulation was seen only in the loss group 
(Fig. 4A). In the gene dosage driven pattern, on the other hand, only loss was associated with 
downregulation, whereas hypermethylation seemed to have no effect. The strongly gene 
dosage regulated genes identified in previous work16, THOC7 and PSMD6, showed this 
pattern. Downregulation by loss was seen in both the hypermethylated and not 
hypermethylated group for THOC7, but only in the not hypermethylated group for PSMD6 
(Fig. 4B). Individual effect of either methylation or gene dosage on the expression level was 
thus suggested for five genes within the region.  
 
For FHIT, LRIG1, and ADAMTS9 a combined regulation pattern was observed where both 
hypermethylation and loss were associated with downregulation. For FHIT and ADAMTS9, 
downregulation by methylation was seen in the no loss group only, whereas downregulation 
by loss was seen in the not hypermethylated group (Fig. 4C). Hence, although both events 
were suggested to influence expression, only an individual effect depending on gene dosage 
and methylation status could be detected. Another variant of this pattern was seen for LRIG1, 
where significant downregulation occurred only when both events where present in the same 
tumors (Fig. 4C). The downregulation was not significant when only hypermethylation or loss 
was found. The two events combined may therefore possibly enhance the transcriptional 
repression, leading to a significant downregulation.  
 
Since many tumors were aneuploid and therefore could have unaffected alleles in cases of 
both hypermethylation and loss, the analysis was also performed for the 38 near diploid 
tumors separately, for the 8 genes with a defined regulation pattern (Table S3). The same 
regulation patterns emerged, except for THOC7, which was on the borderline of significance 
for one of the combinations (data not shown). For GPR27, ZNF717, and FHIT, some tumor 
groups were too small (n ≤ 3) for statistical analysis. Moreover, the expression levels were 
similar regardless of whether only the near diploid or all tumors were considered, also for the 
combined loss and hypermethylated group.    
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Relationship to clinical outcome 
Loss of 3p11.2-p14.2 has previously been shown to be associated with poor outcome for the 
patients included in the present study 16. To investigate whether inclusion of methylation data 
could add to the prognostic value of the loss, we selected the eight genes with a defined 
regulation pattern (Fig. 4, Table 1) and generated survival curves for patients with different 
combinations of gene dosage and methylation status. For LRIG1, both loss and 
hypermethylation were associated with poor outcome in separate survival analyses (Fig. 5A, 
B). Moreover, a large difference in outcome between hypermethylated and not 
hypermethylated tumors was seen within the no loss group, where patients with 
hypermethylation had a poor survival compared to the patients without hypermethylation 
(Fig. 5C). The lowest survival probability was observed for the patients with loss, but in these 
cases the methylation status seemed to have only a minor effect on the outcome. In 
accordance with this, we also found that reduced gene expression of LRIG1 was associated 
with poor survival (Fig. 5D). For the other genes, no relationship to outcome was seen when 
the methylation status or the combined gene dosage and methylation status was considered.  
 
C3orf14 methylation and suppressor function 
The finding of genes with a methylation driven regulation pattern, opened for the possibility 
to discover tumor suppressor genes that have not been identified in the search for targets of 3p 
loss. C3orf14, GPR27 and ZNF717 emerged as novel methylation regulated suppressor 
candidates with unknown function. C3orf14 had the highest number of hypermethylated CpG 
sites and its expression was more strongly associated with methylation. The gene was 
therefore selected for further investigations. To better understand the regulation pattern of 
C3orf14, the methylation data of the 11 CpG sites retained in the data set after data 
preprocessing were analyzed in more detail. The frequency of hypermethylation differed 
considerably across the sites, ranging from 13% to 86% in cohort 1 and from 3% to 86% in 
cohort 2 (Fig. 6A; Table S2). The methylation level of the sites also differed and was strongly 
correlated to the total number of hypermethylated sites in both cohorts (Fig. 6B and data not 
shown). This heterogeneous methylation pattern could be clearly seen when considering the 
β-distribution across all patients, where a distinct group of hypermethylated tumors with a 
wide range of methylation levels appeared for the most hypermethylated sites (Fig. 6C). Both 
number of hypermethylated sites and their methylation level were associated with expression 
in both cohorts (Fig. 6D, E), suggesting that the highly heterogeneous methylation across 
CpG sites and tumors is of relevance for gene silencing.  
 
The role of C3orf14 silencing was further studied in early- and late-passage FK16A cells, 
which mimic preinvasive stages in cervical carcinogenesis. C3orf14 knockdown led to 
increased invasive capacity in both passages, as shown for two representative experiments in 
Figure 6F. Cell viability and, hence, the proliferation rate was not affected by the knockdown 
(Fig. 6G). Downregulation of C3orf14 may therefore possibly promote tumor invasiveness at 
early stages of the disease, in line with a suppressor function of the gene. 
 
7 
 
Discussion 
The complete methylation mapping of promoter CpG sites performed in our work showed that 
the 3p11.2-p14.2 region was subjected to differential methylation in cervical cancer, both 
when comparing tumors and normal cervical tissue and different tumors in patient cohorts. By 
combining the data with gene dosage and expression, we identified genes for which 
methylation and loss were suggested to cooperate in the transcriptional regulation, and other 
genes for which an individual effect of the events was likely. Considerable efforts have been 
made in previous studies to reveal how genes within the region are regulated, by focusing on 
individual genes 21 or large scale gene dosage data 16. Our study demonstrates a potential of 
integrating large scale methylation and gene dosage data to achieve a more complete 
understanding of the regulatory mechanisms. Moreover, the detailed information provided by 
the Illumina technology opened for the discovery of novel methylation regulated tumor 
suppressor genes, which may play a role in cervical carcinogenesis.  
 
Promoter hypermethylation at 3p11.2-p14.2 was found to be a frequent event, affecting more 
than half of the 48 genes with promoter associated CpG-sites in two independent data sets. 
For many genes, hypermethylation was seen in the majority of patients and was even more 
common than chromosomal loss. Moreover, a small, but significant, increase in the overall 
hypermethylation frequency was found with increasing tumor stage. The hypermethylated 
state may therefore pose a selection pressure on the way from normal epithelial cells to 
invasive cancer, as indicated by previous studies based on individual genes, such as FHIT, 
ROBO1, and FAM19A4 17-19, and possibly towards increased malignancy. It should be 
emphasized that although most islands were represented on the array, not all sites within the 
islands were included. It was therefore not possible to judge whether the CpG sites included 
were representative of the whole island.  
 
More than half of the identified hypermethylated genes (17 out of 26) were found to be 
downregulated in tumors compared to normal tissues. In addition, an association between 
methylation and expression level was seen in tumors for some of the genes. It is therefore 
likely that the methylation plays a direct role in gene silencing at this region and participates 
in generation of the transcriptional program that drives cervical carcinogenesis. Moreover, the 
finding of candidate targets of the recurrent 3p11.2-p14.2 loss, i.e. GBE1, THOC7, and 
PSMD6 16, among the hypermethylated genes, points to the necessity to integrate gene dosage 
into the analysis to better understand the role of methylation in gene regulation. The exact 
transcript variant which is regulated by methylation could not be determined from our data, 
since the expression probes often cover several variants. Reverse transcription (RT) PCR with 
primers specific for each individual variant would clarify this.     
 
In the methylation driven regulation pattern, which was suggested for C3orf14, GPR27, and 
ZNF717, only hypermethylation and not loss was associated with downregulation. Promoter 
methylation therefore seemed to play a major role in gene regulation, and the 
hypermethylated state probably exerts a selection pressure during carcinogenesis. This is in 
contrast to the findings for THOC7 and PSMD6, where a gene dosage driven regulation 
pattern was suggested. For these genes, methylation seemed to have no effect on the 
expression level, although hypermethylation was found in more than half of the tumors. The 
meaning of methylation is not clear for these genes.  
 
A combined methylation and gene dosage driven regulation pattern was suggested for FHIT, 
ADAMTS9, and LRIG1. For FHIT and ADAMTS9, methylation seemed to be an important 
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regulation mechanism in cases without loss, while loss is probably important in non-
methylated tumors. Both genes have been shown to be regulated by promoter methylation in 
previous work 17,22 and their downregulation has been associated with suppressed proliferation 
and increased apoptosis in experimental studies 23-25. Our data indicate that both loss and 
hypermethylation can lead to downregulation of FHIT and ADAMTS9 and possibly be 
alternative routes in tumor progression. No significant increase in downregulation could, 
however, be seen in cases with both loss and hypermethylation, as compared to those with 
only one of the events.  
 
For LRIG1, on the other hand, the lowest expression was observed in the loss group in cases 
with hypermethylation. The presence of the two events in the same tumors therefore 
apparently poses a strong selection pressure. This hypothesis was strengthened by the results 
from the survival analyses, where loss and methylation were suggested to have prognostic 
impact when analyzed separately, and the worse prognosis was seen for patients with both 
methylation and loss. In addition, patients with hypermethylation without loss had an 
intermediate outcome that could probably be explained because the downregulation in this 
group was on the borderline of significance. LRIG1 has been proposed to be an important 
tumor suppressor in many cancer types 26, and low protein expression has been associated 
with poor prognosis of early stage cervical cancer 27 in accordance with our gene expression 
data. Gene dosage alteration has been suggested as a major regulation mechanism of LRIG1 
and a prognostic factor in breast cancer 28. Our study indicates a role of methylation in 
addition to loss in gene regulation and proposes a possible use of methylation combined with 
loss as a prognostic factor in cervical cancer.  
 
C3orf14 appeared to be the most strongly methylation regulated gene in both patient cohorts, 
showing the largest number of CpG sites with a highly significant correlation between 
methylation and expression. The number of hypermethylated CpG sites as well as their 
methylation level varied considerably across the tumors, and both factors were associated 
with gene expression. These observations are in accordance with a model describing gene 
silencing by methylation as a dynamic process where methylation is gradually spread to more 
CpG sites along the DNA molecule, to more alleles and to a larger part of the tumor 10,29.  
 
The methylation driven downregulation of C3orf14, GPR27, and ZNF717 implies a 
suppressor function of the genes. The genes have not been studied in cervical cancer before 
and emerge as novel suppressor candidates in the disease. GPR27 encodes a G protein-
coupled receptor, which probably has a role in insulin production and/or secretion 30, whereas 
the zinc finger protein ZNF717 may be involved in transcriptional regulation and has been 
found to be affected by recurrent mutations in gastric tumors 31. C3orf14 encodes an 
uncharacterized protein and was listed as one out of many hypermethylated and 
downregulated genes in a previous whole-genome study of glioblastomas 32, in accordance 
with our results. We further found that knockdown of C3orf14 increased the invasiveness of 
early and late passages of FK16A cells, which are models of intraepithelial cervical lesions. 
Silencing of C3orf14 therefore possibly contributes to invasive growth. Loss of 3p11.2-p14.2 
apparently emerges early during the invasive stage of tumor development, and affects genes 
involved in cell proliferation and anti-apoptosis 16. The fact that C3orf14 is located at the most 
frequently lost region, but is not regulated by the loss, may imply that C3orf14 methylation 
occurs first. Hence, it is tempting to speculate that C3orf14 methylation and consequently 
downregulation pose a selection pressure prior to the loss by being directly involved in the 
invasion process. 
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In conclusion, methylation and loss seem to cooperate in silencing of specific genes within the 
3p11.2-p14.2 region. To better understand the regulation of these genes during tumor 
progression and develop robust prognostic markers based on genetic or epigenetic events, 
combined information of both events would be required. For other genes, methylation and 
loss probably play individual roles in gene silencing. In particular, novel methylation 
regulated candidates, like C3orf14, GPR27, and ZNF717, were suggested. Further exploration 
of these genes may lead to a better understanding of cervical carcinogenesis. 
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Materials and methods 
Patients  
Tumor specimens were achieved from 270 patients with locally advanced squamous cell 
carcinoma (SCC) of the uterine cervix who were prospectively recruited to our 
chemoradiotherapy protocol. The patients were divided into an investigation cohort of 149 
patients (cohort 1) and a validation cohort of 121 patients (cohort 2), based on the Illumina 
beadarray version used for gene expression profiling (Table S1). The primary tumor and 
elective pelvic areas were treated with 50 Gy of external irradiation in 25 fractions, and 
metastatic lymph nodes received additional 14 Gy. Brachytherapy, 25 Gy, to the primary 
tumor was delivered in five fractions of 5 Gy. Concomitant chemotherapy with cisplatin (40 
mg per m2) was administered according to tolerance. Standard procedures including imaging 
and clinical examination were applied for follow up. One to four biopsies were taken at 
different locations of the tumor at the time of diagnosis, immediately frozen in liquid 
nitrogen, stored at -80ºC, and used for DNA copy number, gene expression, and methylation 
analyses. DNA and RNA from different biopsies of the same tumor were pooled. The clinical 
protocol was approved by the Regional Committee for Medical Research Ethics in southern 
Norway (REK no. S-01129). Written informed consent was obtained from all patients.  
 
DNA methylation  
DNA methylation profiling of 270 tumors was performed using the Illumina Infinium Human 
Methylation450 beadarrays (Illumina Inc., San Diego, CA) 20. DNA was isolated according to 
a standard protocol with proteinase K, phenol, chloroform, and isoamylalcohol (cohort 1) 33, 
or by the use of PureLinkTM Genomic DNA Mini Kit (Life Technologies, Carlsbad, CA, 
USA) (cohort 2). Purified DNA quality and concentration were assessed using the Quant-
iTTMPicoGreen® dsDNA Assay Kit (Life Technologies, Carlsbad, CA, USA) prior to 
bisulfite conversion. One µg of DNA was bisulfite converted using the EZ DNA Methylation 
Kit (Zymo Research, Orange, CA, USA) according to the manufacturer’s protocol. The use of 
different DNA isolation methods in the two cohorts did not influence the quality of bisulfite 
converted DNA, as demonstrated by the equal fragment length produced by methylation-
specific PCR for selected primers (Fig. S2). Four µl of bisulfite converted sample was whole-
genome amplified, enzymatically digested, and hybridized to the array before single 
nucleotide extension was performed. The array data are available in the Gene Expression 
Omnibus (GEO) through accession number GSE68339. 
 
Preprocessing of methylation data 
Preprocessing of the methylation data, involving quality control, probe filtering, signal 
correction, and normalization was performed in R (version 2.15.1) using the pipeline 
developed by Touleimat & Tost 34. In brief, for quality control, probes with less than three 
functional arraybeads were considered non-functional and assigned a detection p-value of 1. 
Samples having > 80% high quality probes (detection p-value < 0.01) were defined as of 
“good quality”. All samples complied with this criterion. Poorly performing probes with a 
detection p-value > 0.05 in more than 20% of the samples, probes located 10bp or closer to 
known genetic variants and allosomal probes on the Y chromosome were removed. A color 
balance adjustment between the two channels was performed followed by a separate color 
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background adjustment based on negative control probes provided by Illumina. Finally, subset 
based quantile normalization was applied to correct for the shift in signal between infinium I 
and infinium II probes and normalize between samples. For probe category construction, 
CpG-categories were built using the “relationToCpG” annotation from the Illumina file. Only 
CpGs within the 3p11.2-14.2 region mapping to promoter regions, which we defined as 
located closer than ±2kb from the transcription start site, were included in the further 
analyses.   
 
As a measure of methylation, β-values were used. β represents fraction of methylated DNA 
molecules at a specific CpG site and ranges from 0 (no methylation at any allele) to 1.0 
(complete methylation of all alleles). An interquartile range (IQR) > 0.08 for each site was 
claimed to ensure sufficient dynamics in β across patients.    
 
DNA copy number  
DNA copy number profiling of 75 tumors in cohort 1 was performed by array comparative 
genomic hybridization (aCGH) and has been presented previously 16.  Absolute DNA copy 
numbers were calculated from the aCGH ratios by the GeneCount algorithm, and were 
corrected for tumor ploidy, as determined by flow cytometry, and normal cell fraction of the 
samples 35. Samples showing two distinct G1 peaks in the DNA histogram by flow cytometry 
were classified as aneuploid, and the ploidy was determined from the position of the G1 peak 
of the aneuploid cells relative to the corresponding peak of the diploid cells. Samples with a 
single G1 peak were classified as near diploid. Normal cell fraction was estimated by 
GeneCount prior to copy number calculations. Absolute gene dosages were calculated by 
dividing the copy numbers with ploidy. Gains and losses were scored by using gene dosage 
thresholds of 1.1 and 0.9, respectively, taking into account an uncertainty in the ploidy 
measurement of approximately 10%. The array data are available from the ArrayExpress 
repository through the accession number E-MTAB-3531. 
 
Gene expression 
Gene expression profiling of 147 tumors in cohort 1 and 121 tumors in cohort 2 was 
performed using the Illumina HumanWG-6 v3 (cohort 1) and HumanHT-12 v4 (cohort 2) 
expression beadarrays with approximately 48 000 transcripts (Illumina Inc., San Diego, CA). 
All samples had more than 50% tumor cells in haematoxilin and eosin stained sections. This 
selection may have led to some bias in the results, but was chosen to reduce the influence of 
different normal cell proportion across the samples. Total RNA was isolated by the use of 
Trizol reagent (Life Technologies, Carlsbad, CA) followed by LiCl precipitation (cohort 1) or 
miRNeasy mini kit (Qiagen, Germantown, MD) (cohort 2). Hybridization, scanning, signal 
extraction and normalization were performed as described 5. The array data are available in 
GEO (GSE68339).  
 
External data sets 
Four data sets, GSE6791, GSE7803, GSE9750, and GSE46306, were retrieved from the GEO 
database. The GSE46306 data set included methylation (β-values) of 20 human 
papillomavirus (HPV) negative normal cervical samples determined with the Illumina 
Infinium Human Methylation450 beadarrays (Illumina Inc.) 36, and was used to determine 
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methylation status of the tumors in cohorts 1 and 2 as compared to normal tissue. The 
GSE6791 37, GSE7803 38, and GSE9750 39 data sets included gene expression of normal and 
cancerous cervical samples determined with Affymetrix U133 arrays (Affymetrix, Santa 
Clara, CA) and were used to investigate expression changes of hypermethylated genes in 
tumors as compared to normal tissue. The data sets were based on 8, 10, and 21 normal 
samples and 20, 21, and 32 tumor samples in GSE6791, GSE7803, and GSE9750, 
respectively. Using the online tool GEO2R (www.ncbi.nlm.nih.-gov/geo/geo2r), the 
differences in gene expression between normal and cancer samples were estimated. An 
adjusted p-value ≤ 0.10 was considered statistically significant. The normal cervical samples 
in all data sets were collected from pap smears or hysterectomy specimens and were enriched 
for epithelial cells by microdissection. 
 
Cell lines and siRNA transfection 
The HPV16-immortalised keratinocyte cell line FK16A was used to explore the functional 
meaning of C3orf14 silencing. The morphology of the FK16A cells in 3D cultures is 
reminiscent of dysplastic precancerous lesions of the cervix 40. The cells are immortalized and 
telomerase positive, like a subset of CIN3 lesions 41, but not tumorigenic. Early- and late-
passage cells, FK16A passage 40/42 and FK16A passage 304, respectively, were included and 
cultured as described previously 40. Both passages still express C3orf14. For knockdown of 
C3orf14, FK16A cells were seeded in a 6-well plate and transfected with a pool of C3orf14 
specific siRNAs (#L-017892-02-0005, GE Healthcare Dharmacon Inc., Lafayette, CO, USA) 
(Fig. S3) and controls, using DharmaFECT2 transfection reagent (Thermo Fisher Scientific, 
Waltham, MA, USA). Control cells were transfected with ON-TARGETplus Non-targeting 
Pool (#D-001810-10-05, GE Healthcare Dharmacon Inc.). The transfected cells were 
harvested after 48 hours for RNA isolation, or replated for invasion and proliferation analysis. 
 
Knockdown was confirmed with RT PCR, using the Primer Express software v3.0 (Applied 
Biosystems) to select primers for C3orf14 (Fig. S3). The U1 small nuclear ribonucleoprotein 
A (snRNP U1A) 42 was used as endogenous control. Total RNA was isolated using TRIzol 
reagent (Life Technologies), according to the manufacturer’s instructions. cDNA synthesis 
from 200 ng RNA and PCR amplification in 40 cycles were performed essentially as 
described 42, with annealing temperatures of 58°C and 60°C for snRNP U1A and C3orf14, 
respectively. The PCR products were separated on a 2% agarose gel. 
 
Functional assays 
Cellular invasion was determined using transwells containing a fluorescence blocking filter 
(HTS FluoroBlok; Falcon, BD Biosciences, Breda, The Netherlands). The bottom of the 
transwells was coated with fibronectin (2µg/ml solution in PBS; MP Biomedicals, Illkrich, 
France) and the top compartment was coated with collagen (50µg/ml solution in PBS; 
Collagen Type 1 rat tail, BD Biosciences) to mimic tumor matrices in vivo. FK16A cells in 
medium without supplements were added to the top compartment, and complete medium was 
added to the bottom. Calcein AM (Molecular Probes, Invitrogen, Leiden, The Netherlands) 
was used for fluorescent labeling of the cells. The fluorescence intensity of the bottom relative 
to the top compartment after 48 h was used as a measure of invasion.  
 
Cell proliferation was measured using a colorimetric (MTT-tetrazolium) assay (MP 
Biomedicals) as described 7. In this assay, the amount of dye conversion, as measured by the 
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optical density at a wavelength of 540 nm, is directly related to the number of viable cells in 
each well. Totally 2500 FK16A cells were seeded in triplicate in 96-well plates and assayed 
for MTT conversion at day 0, 2, and 5. The proliferation rate was determined by subtracting 
the measurement of day 0 from that of the other time points.  
Statistics 
Spearman’s rank correlation analysis was applied to search for correlations between 
methylation (β-values), gene dosage, and expression. The methylation probes were linked to 
the gene expression probes by using the HumanHT-12v4 Methyl450K lookup table provided 
by Illumina, where missing probes were added manually. For comparison of patient groups 
with different combinations of loss and methylation, Welch’s t-test was used. Both analyses 
included adjustment of the  p-values by the algorithm developed by Benjamini and Hochberg 
to control the false discovery rate (FDR) 43, and an adjusted  p ≤ 0.10 was used for selection 
of significant correlations and differences. For analyses of individual CpG sites, Spearman’s 
rank or Pearson’s correlation analysis was performed with a significance level of p < 0.05. 
Survival curves were generated by Kaplan-Meier analysis and compared using log-rank test. 
Progression free survival; i.e., the time between diagnosis and the first event of locoregional 
and/or distant relapse, was used as end point. Totally 20 patients died of causes not related to 
cancer and were therefore censored.  
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Figure 1. Hypermethylated CpG sites. Methylation status of 150 CpG sites on 26 genes for 
149 cervical cancer patients in cohort 1. Patients are shown in columns and CpG sites found 
to be hypermethylated in tumors compared to normal tissue in at least 10% of the patients are 
ordered by chromosomal location in rows with gene symbols indicated. Hypermethylated 
(M) and not hypermethylated (NM) sites are indicated with red and blue color, respectively. 
Frequency of patients with hypermethylation and chromosomal loss is shown for each site by 
the black and green curves, respectively.  
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Figure 2. Validation of hypermethylation frequency in cohort 2. Frequency of 121 cohort 
2 patients with hypermethylation versus the corresponding frequency for 149 cohort 1 
patients. Totally 150 CpG sites found to be hypermethylated in cohort 1 are shown, and each 
dot represents the hypermethylation frequency of an individual site. Pearson’s correlation 
coefficient and p-value are indicated. Line of unity is included. 
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Figure 3. Identification and validation of silenced genes. (A) Difference in expression of 
26 hypermethylated genes between tumors and normal cervical samples. The mean fold 
change based on three external datasets (GSE6791, GSE7803, GSE9750) is shown for each 
gene. Seventeen genes which were significantly downregulated at an adjusted p ≤ 0.10 in at 
least one of the datasets are indicated in red and their symbol is listed. (B) Correlation 
coefficients (rho) from Spearman’s rank correlation analysis of methylation (β-value) against 
expression for 26 hypermethylated genes in 147 cervical tumors (cohort 1). Only negative 
correlations are shown, and in cases of several methylation and expression probes for the 
same gene, the most significant probes are presented. The horizontal line indicates the cut-off 
significance level, corresponding to rho = -0.20 (adj p ≤ 0.10). Eight significant genes are 
indicated in red and their symbol is listed. (C) Schematic illustration of the CpG sites for 6 
significant genes in (B), which were validated in cohort 2. Significant CpG sites are indicated  
in green (adj p ≤ 0.10) and not significant sites in blue for 147 patients in cohort 1 and 121 
patients in cohort 2. Sites in white were filtered during preprocessing due to their location 
closer than 10bp from a SNP or low variation across the patients (hatched white; IQR<0.08). 
Grey sites were hypermethylated in <10% of the patients. TSS: transcription start site.  
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Figure 4. Individual and combined effect of loss and hypermethylation on gene 
expression.  Box plots of gene expression in four groups of tumors with different 
combination of gene dosage and methylation status, demonstrating individual effect of 
methylation (A), individual effect of gene dosage (B), and combined effect of methylation 
and gene dosage (C) on gene expression. Totally 73 tumors from cohort 1 were included, for 
which gene expression, gene dosage, and methylation data were available.  NL: no loss; L: 
loss; NM: not hypermethylated; M: hypermethylated. The median expression value of each 
group is indicated by the horizontal lines, and the edges of the boxes represent the first and 
third quartiles. P-values from Welch’s t-test are indicated. All indicated differences had an 
adjusted p ≤ 0.10. 
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Figure 5. Individual and combined effect of LRIG1 loss and hypermethylation on 
clinical outcome. Kaplan-Meier curves of progression free survival for cervical cancer 
patients (cohort 1) with and without loss of LRIG1 (A), with and without hypermethylation 
of LRIG1 (B), the two combined (C), and high and low LRIG1 expression (D). P-values in 
log-rank test and number of patients are indicated. NL: no loss; L: loss; NM: not 
hypermethylated; M: hypermethylated.  
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Figure 6. Methylation characteristics and suppressor function of C3orf14. (A) Frequency 
of cervical cancer patients with hypermethylation of individual CpG sites ordered by 
location. (B) Methylation (β-value) against number of hypermethylated CpG sites. (C) 
Density plots (kernel density estimation with band width 0.02, black line; histogram, grey 
bars) of C3orf14 methylation in normal cervical tissue from GSE46306 (left) and tumors in 
cohort 1 (right). The blue lines indicate cut-off β-value for scoring hypermethylation. (D) 
C3orf14 expression against number of hypermethylated CpG sites. (E) C3orf14 expression 
against methylation (β-value). Invasion (F) and cell viability (G) of control and C3orf14 
siRNA treated FK16A cells at early (p40/42) and late (p304) passages. The columns and bars 
show the mean and standard deviation of triplicates for one representative experiment for 
each passage. The difference between siRNA treated and control cells was significant for 
invasion (p42: p=0.010, p304: p=0.006, t-test), but not for cell viability. In B, C, and E, 
methylation data of the CpG site correlating most strongly with gene expression were used. 
In B, D, and E, correlation coefficient (rho) and p-value in Spearman’s rank correlation 
analysis are indicated. In A-E, data from cohort 1 are presented; similar results were found 
for cohort 2.  
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Tables 
 
Table 1. Hypermethylated genes on 3p11.2-14.2 in cervical cancer 
Gene 
symbola Gene name 
Hypermethylation 
frequency (%) b 
Regulation 
pattern c 
FHIT Fragile histidine triad 18.5 Combined 
C3orf14 Chromosome 3 open reading frame 14 48.6 Methylation 
FEZF2 FEZ family zinc finger 2 81.4 ND 
CADPS Ca++-dependent secretion activator 78.4 ND 
SYNPR Synaptoporin 74.8 ND 
THOC7 THO complex 7 homolog (Drosophila) 55.0 Gene dosage 
ATXN7 Ataxin 7 55.0 ND 
PSMD6 Proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 46.3 Gene dosage 
PRICKLE2 Prickle homolog 2 (Drosophila) 26.7 ND 
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 63.6 Combined 
MAGI1 Membrane associated guanylate kinase, WW and PDZ domain 
containing 1 
51.0 ND 
LRIG1 Leucine-rich repeats and immunoglobulin-like domains 1 63.1 Combined 
FAM19A1 Family with sequence similarity 19 (chemokine (C-C motif)-like), 
member A1 
23.5 ND 
FAM19A4 Family with sequence similarity 19 (chemokine (C-C motif)-like), 
member A4 
82.4 ND 
MITF Microphthalmia-associated transcription factor 16.6 ND 
FOXP1 Forkhead box P1 45.2 ND 
EIF4E3 Eukaryotic translation initiation factor 4E family member 3 15.4 ND 
GPR27 G protein-coupled receptor 27 16.8 Methylation 
PROK2 Prokineticin 2 57.9 ND 
PPP4R2 Protein phosphatase 4, regulatory subunit 2 20.8 ND 
PDZRN3 PDZ domain containing ring finger 3 70.0 ND 
ZNF717 Zinc finger protein 717 69.4 Methylation 
ROBO2 Roundabout, axon guidance receptor, homolog 2 (Drosophila) 81.2 ND 
ROBO1 Roundabout, axon guidance receptor, homolog 1 (Drosophila) 89.3 ND 
GBE1 Glucan (1,4-alpha-), branching enzyme 1 47.7 ND 
CADM2 Cell adhesion molecule 2 79.0 ND 
a
 Genes are listed by chromosomal location. 
b
 Based on cohort 1of 149 patients. 
c
 Combined, combined methylation and gene dosage driven regulation; Methylation, methylation driven regulation; Gene 
dosage, gene dosage driven regulation; ND, none detected    
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Supplementary Figure S1. 3p chromosomal loss and hypermethylated CpG sites in 
cervical cancer stratified by FIGO-stage. (A) Frequency of patients with chromosomal loss 
of 3p for FIGO-stage 1 (n=5), 2 (n=41), and 3&4 (n=29). (B) Frequency of patients with 
hypermethylation of 3p genes for FIGO-stage 1 (n=10), 2 (n=93), and 3&4 (n=46). CpG sites 
found to be hypermethylated in tumors compared to normal tissue in at least 10% of the 
patients are included and the gene symbols are indicated. (C, D)  Box plots showing 
frequency of patients with chromosomal loss (C)  and hypermethylation (D) of 3p stratified 
by FIGO-stage. The median frequency over the entire chromosomal region (C) and the 26 
hypermethylated genes (D) is indicated for each group by the horizontal lines, and the edges 
of the boxes represent the first and third quartiles. P-values from Welch’s t-test are indicated. 
Blue: stage 1; Red: stage 2; Green: stage 3&4. 
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ACTB PSMD6
Cohort 1 Cohort 1Cohort 2 Cohort 2
A
B
Primers used for methylation-specific PCR
Genea Primer sequences, 5’-3’ Amplicon (bp)b Tm (°C)c 
ACTB_F TGGTGATGGAGGAGGTTTAGTAAGT 133 60 ACTB_R AACCAATAAAACCTACTCCTCCCTTAA 
 
 
  PSMD6_F GTGTAAATTTTTCGATTGGTAGATAGAC 154 60 PSMD6_R CGACCTTTACCATCATTACATCG 
aF: Forward primer, R: Reverse primer 
bbp: Base pair 
cTm: Melting temperature 
 
Supplementary Figure S2. Methylation-specific PCR (MSP) on bisulfide converted DNA 
isolated by different methods. (A) MSP products for selected tumors from cohort 1 and 
cohort 2 using primers for ACTB (β-actin) and PSMD6. DNA from tumors in cohort 1 was 
isolated using proteinase K, phenol, chloroform, and isoamylalcohol, whereas DNA from 
tumors in cohort 2 was isolated using PureLinkTM Genomic DNA Mini Kit. (B) Primer 
sequences, amplicon length, and melting temperature for ACTB and PSMD6.  
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Primers for RT-PCR 
Target Primer sequences, 5’-3’ Size (bp) 
Tm 
(°C) 
GC 
(%) Amplicon (bp) 
U1A1_F 5’-CAGTATGCCAAGACCGACTCAGA-3’ 23 61.83 52.17 
215  
U1A2_R 5’-GGCCCGGCATGTGGTGCATAA-3’ 21 70.23 61.9 
C3orf14_F 5’-GAAAAGGCATCTCAACTCCAAA-3’ 22 58.86 40.91 
111  
C3orf14_R 5’-AAGTGGGTGAATCCTGGTCTG-3’ 21 58.7 52.38 
 
B
The individual siRNA’s that constitute the SMARTpool for C3orf14 
SMARTpool siRNA 
catalog number Sequence Targets 
J-017892-17 AAAAUGAGGCACAGCGAUA  
NM_020685 
NM_001291941 
NM_001291942 
J-017892-18 UCGAUUAUCUCCUAAGUGA  
NM_020685 
NM_001291941 
NM_001291942 
J-017892-19 AGAAUAAAUUGGGUGAUCA 
NM_020685 
NM_001291941 
NM_001291942 
NM_001291943 
J-017892-20 GAGACUCGUUACUGGGCAU  
NM_020685 
NM_001291941 
NM_001291942 
 
 
 
Supplementary Figure S3. Knockdown of C3orf14.  (A) Catalog number, sequence, and 
target transcripts for the individual siRNA’s that constitute the SMARTpool for C3orf14. All 
four transcript variants of the gene are included in the SMARTpool and therefore suppressed 
by siRNA transfection. (B) Primers for RT-PCR to confirm knockdown of C3orf14.  F: 
forward; R: reverse; Tm: melting temperature. (C) C3orf14 expression in control and siRNA 
treated FK16A cells at early (p40) and late (p298) passages for two typical experiments. 
SnRNP U1A was used as endogenous control. 
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Supplementary Table S1. Cervical cancer patient and tumor characteristics 
Characteristic Cohort 1 
a
 
(n=149) 
Cohort 2  
(n=121) 
FIGO stage (n) 
 
 
1B 10 13 
2 93 80 
3 38 23 
4A 8 5 
 
 
 
Tumor sizeb: vol (cm3)c, diameter (cm)d 
 
 
Median 43.6, 4.4 30.8, 3.9 
Range 1.9-321, 1.5-8.5 2.8-267, 1.8-8.0 
 
 
 
Pelvic lymph node statusb (n) 
 
 
Positive 63 55 
Negative 86 66 
 
 
 
Age 
 
 
Median 55 53 
Range 24-82 22-84 
 
 
 
Observation time (months)e 
 
 
Median 70.4 44.1 
Range 37-152 23-119.9 
   
Relapse (distant and/or local) 46 32 
a Patients in cohort 1 were also included in [1] 
bTumor size and lymph node status were determined from pretreatment magnetic 
resonance (MR) images. 
c
 Volume was calculated based on 3 orthogonal diameters (a,b,c) as V=(π/6)*abc.  
d
 Diameter was calculated from tumor volume V=(4π/3)*r3. 
e
 Patients who either got relapse or died of causes not related to cancer are not included. 
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Supplementary Table S2 - Hypermethylation and correlation to gene expression for individual CpG sites at 3p11.2-p14.2 in cervical cancer 
* Spearman's rank correlation between methylation (β) and gene expression           
CpG site ID Gene symbol Location  Relation to UCSC CpG-Island 
Hypermethylation frequency 
(%) Gene expression correlation* 
    MAPINFO   Cohort 1 Cohort 2 Cohort 1 Cohort 2 
            Rho Adj P Rho Adj P 
cg25736251 FHIT 61235869 N_Shore 22.1 20.7 -0.40 0.0000 -0.32 0.0029 
cg15570148 FHIT 61235985 N_Shore 14.8 13.2 -0.38 0.0000 -0.31 0.0044 
cg07212940 C3orf14 62304165 N_Shore 13.4 19.8 -0.46 0.0000 -0.44 0.0000 
cg25119986 C3orf14 62304264 N_Shore 13.4 3.3 -0.28 0.0053 -0.15 0.3256 
cg11120913 C3orf14 62304470 N_Shore 51.7 55.4 -0.77 0.0000 -0.66 0.0000 
cg26896572 C3orf14 62304515 Island 63.1 66.9 -0.79 0.0000 -0.71 0.0000 
cg01384143 C3orf14 62304554 Island 75.2 81.8 -0.73 0.0000 -0.64 0.0000 
cg02221302 C3orf14 62304629 Island 85.9 86.0 -0.63 0.0000 -0.55 0.0000 
cg15059608 C3orf14 62305003 S_Shore 52.3 47.9 -0.76 0.0000 -0.60 0.0000 
cg22751696 C3orf14 62305147 S_Shore 45.0 52.9 -0.75 0.0000 -0.62 0.0000 
cg01181009 C3orf14 62305213 S_Shore 37.6 40.5 -0.67 0.0000 -0.54 0.0000 
cg12845975 C3orf14 62305226 S_Shore 27.5 33.9 -0.63 0.0000 -0.43 0.0000 
cg14590206 C3orf14 62305285 S_Shore 69.1 67.8 -0.36 0.0001 -0.20 0.1182 
cg02083234 FEZF2 62357769 Island 68.5 79.3 -0.12 0.4323 -0.02 0.9484 
cg18104012 FEZF2 62358241 Island 99.3 98.3 -0.09 0.6841 0.01 0.9791 
cg26136365 FEZF2 62358379 Island 86.6 77.7 -0.19 0.1316 -0.04 0.8922 
cg18902742 FEZF2 62358610 Island 79.2 84.3 -0.06 0.7233 0.06 0.8065 
cg19629292 FEZF2 62358980 Island 77.9 79.3 -0.15 0.2808 0.06 0.8365 
cg15812348 FEZF2 62359390 Island 77.9 85.1 -0.09 0.6466 -0.02 0.9365 
cg19227130 FEZF2 62359392 Island 96.6 99.2 -0.09 0.6425 -0.03 0.9142 
cg06423920 FEZF2 62359420 Island 63.8 65.3 -0.14 0.3109 0.01 0.9787 
cg24705960 FEZF2 62359456 Island 100.0 99.2 -0.13 0.4087 0.02 0.9498 
cg11374425 FEZF2 62359677 Island 100.0 100.0 -0.16 0.2144 0.06 0.8523 
cg08252579 FEZF2 62359773 Island 91.3 94.2 -0.19 0.1316 -0.04 0.9020 
cg08681924 FEZF2 62359924 S_Shore 92.6 95.9 -0.15 0.2884 -0.01 0.9704 
cg27564792 FEZF2 62360162 S_Shore 43.0 47.1 -0.13 0.4144 0.05 0.8691 
cg14261840 FEZF2 62360417 S_Shore 79.9 86.0 -0.18 0.1444 -0.03 0.9262 
cg04927889 FEZF2 62360464 S_Shore 83.2 88.4 -0.13 0.4108 -0.08 0.7453 
cg06819546 FEZF2 62360674 N_Shore 83.9 90.1 -0.06 0.7233 -0.19 0.1482 
cg09024435 FEZF2 62360893 N_Shore 60.4 69.4 0.01 0.9698 -0.09 0.7145 
cg04191342 CADPS 62859289 N_Shore 30.2 41.3 -0.11 0.4965 -0.03 0.9297 
cg15997484 CADPS 62859461 N_Shore 54.4 58.7 -0.02 0.8941 0.02 0.9484 
cg27476262 CADPS 62859618 Island 51.0 60.3 0.00 0.9948 0.02 0.9609 
cg15914463 CADPS 62860103 Island 44.3 51.2 0.02 0.9605 0.06 0.8172 
cg13514230 CADPS 62860224 Island 71.8 73.6 -0.07 0.7233 0.08 0.7495 
cg21458907 CADPS 62860802 Island 94.0 93.4 -0.20 0.1042 -0.04 0.8922 
cg15957055 CADPS 62861055 Island 87.9 77.7 -0.15 0.2708 -0.14 0.3553 
cg11905007 CADPS 62861071 Island 94.0 90.1 -0.11 0.5348 -0.16 0.2674 
cg13491481 CADPS 62861142 Island 100.0 100.0 -0.20 0.1093 -0.05 0.8880 
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cg25947544 CADPS 62861145 Island 100.0 100.0 -0.18 0.1607 -0.04 0.8922 
cg02719752 CADPS 62861245 S_Shore 96.0 96.7 -0.11 0.5431 -0.23 0.0585 
cg23825335 CADPS 62861311 S_Shore 100.0 100.0 -0.12 0.4807 -0.19 0.1570 
cg24505341 CADPS 62861544 S_Shore 90.6 93.4 -0.16 0.2267 -0.26 0.0299 
cg21534264 CADPS 62861631 S_Shore 87.9 88.4 -0.09 0.6841 -0.09 0.6998 
cg10748355 CADPS 62861796 S_Shore 99.3 100.0 -0.07 0.7233 -0.21 0.1096 
cg09379755 CADPS 62861925 S_Shore 53.0 61.2 -0.04 0.8433 -0.13 0.4603 
cg22189386 SYNPR 63263752 N_Shore 14.8 22.3 0.07 0.7233 -0.06 0.8570 
cg09462808 SYNPR 63263824 N_Shore 96.0 96.7 0.10 0.6053 -0.05 0.8706 
cg04785972 SYNPR 63263828 N_Shore 71.1 76.9 0.04 0.8433 0.02 0.9484 
cg06314761 SYNPR 63263832 N_Shore 76.5 77.7 0.07 0.7233 -0.04 0.9020 
cg08536228 SYNPR 63264063 Island 96.6 98.3 -0.02 0.9342 -0.07 0.7622 
cg25854303 SYNPR 63264142 Island 81.9 85.1 0.07 0.7233 -0.15 0.3474 
cg15056773 SYNPR 63264249 S_Shore 94.6 94.2 0.00 0.9909 -0.09 0.7145 
cg14183384 SYNPR 63264335 S_Shore 93.3 93.4 -0.04 0.8532 -0.11 0.5617 
cg15772216 SYNPR 63264919 S_Shore 96.0 95.0 0.01 0.9770 -0.16 0.2779 
cg15559684 SYNPR 63428234   90.6 95.0 -0.03 0.8714 -0.12 0.5238 
cg06185146 SYNPR 63428305   11.4 13.2 -0.03 0.8700 -0.04 0.9020 
cg25506386 ATXN7 63849756 Island 55.0 43.8 0.16 0.2385 -0.17 0.2350 
cg25506386 THOC7 63849756 Island 55.0 43.8 -0.01 0.9770 -0.21 0.0975 
cg06286796 PSMD6 64008041 N_Shore 46.3 47.1 -0.21 0.0834 0.12 0.5238 
cg22801134 PRICKLE2 64210439   17.4 12.4 -0.12 0.4275 0.03 0.9020 
cg23047271 PRICKLE2 64210991   32.2 39.7 0.04 0.8460 -0.23 0.0676 
cg25818214 PRICKLE2 64211155   22.1 25.6 -0.03 0.8762 -0.28 0.0136 
cg02147797 PRICKLE2 64211204   26.8 30.6 0.04 0.8348 -0.24 0.0434 
cg07480640 PRICKLE2 64211328   43.6 47.1 -0.05 0.7786 -0.28 0.0136 
cg22083047 PRICKLE2 64211464   18.1 5.8 0.03 0.8799 -0.24 0.0504 
cg22081832 ADAMTS9 64670459 N_Shore 30.9 16.5 0.07 0.7233 -0.23 0.0597 
cg25859972 ADAMTS9 64670515 N_Shore 14.8 12.4 0.07 0.7233 -0.25 0.0354 
cg03427905 ADAMTS9 64671378 Island 57.0 69.4 -0.14 0.3346 -0.31 0.0048 
cg04366011 ADAMTS9 64671477 Island 66.4 75.2 -0.18 0.1438 -0.18 0.1834 
cg12478384 ADAMTS9 64671764 Island 58.4 73.6 -0.17 0.1867 -0.27 0.0254 
cg23070026 ADAMTS9 64672542 Island 65.1 78.5 -0.10 0.5574 -0.37 0.0004 
cg11427510 ADAMTS9 64673495 Island 94.6 99.2 -0.18 0.1468 -0.26 0.0320 
cg21878275 ADAMTS9 64673501 Island 99.3 100.0 -0.12 0.4275 -0.25 0.0432 
cg17626022 ADAMTS9 64673914 Island 100.0 100.0 -0.15 0.2622 -0.19 0.1570 
cg25121125 ADAMTS9 64674314 S_Shore 49.0 64.5 -0.14 0.3423 -0.25 0.0423 
cg15764058 MAGI1 66024691 Island 51.0 55.4 -0.04 0.8532 -0.02 0.9484 
cg06096184 LRIG1 66549732 N_Shore 63.1 49.6 -0.57 0.0000 -0.61 0.0000 
cg01709518 FAM19A1 68053484 N_Shelf 23.5 31.4 -0.11 0.5124 -0.05 0.8864 
cg08495813 FAM19A4 68980320 N_Shore 47.7 62.8 -0.01 0.9698 -0.02 0.9475 
cg01405004 FAM19A4 68980539 N_Shore 73.8 81.8 -0.08 0.7135 -0.03 0.9365 
cg03186486 FAM19A4 68980947 Island 53.0 61.2 -0.08 0.7135 -0.07 0.7757 
cg15356923 FAM19A4 68981011 Island 93.3 98.3 -0.07 0.7233 -0.15 0.3474 
cg23967169 FAM19A4 68981503 Island 79.9 78.5 -0.09 0.6949 -0.07 0.8031 
cg12417685 FAM19A4 68981852 Island 100.0 100.0 -0.08 0.7135 -0.10 0.6721 
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cg12219082 FAM19A4 68981854 Island 99.3 100.0 -0.06 0.7260 -0.10 0.6786 
cg09868336 FAM19A4 68981866 Island 96.6 95.0 0.01 0.9770 -0.11 0.5794 
cg12412079 FAM19A4 68981877 Island 98.7 99.2 -0.01 0.9698 -0.07 0.7728 
cg13921352 FAM19A4 68981890 Island 84.6 90.1 -0.07 0.7233 -0.09 0.7145 
cg20375342 FAM19A4 68981895 Island 82.6 85.1 -0.03 0.8730 -0.07 0.8065 
cg05893614 FAM19A4 68981956 Island 87.2 89.3 -0.04 0.8363 -0.09 0.7145 
cg08038353 FAM19A4 68982064 S_Shore 73.2 85.1 -0.04 0.8433 -0.09 0.6788 
cg03427298 FAM19A4 68982098 S_Shore 83.2 87.6 -0.04 0.8312 -0.03 0.9020 
cg06070625 MITF 69812798   11.4 16.5 0.11 0.5204 0.10 0.6716 
cg09325003 MITF 69812885   32.2 34.7 0.06 0.7233 0.08 0.7599 
cg03831180 MITF 69915302   12.8 12.4 0.04 0.8603 0.09 0.7145 
cg13523819 MITF 69915449   10.1 5.0 0.04 0.8603 -0.05 0.8714 
cg05384123 FOXP1 71294341   14.8 12.4 -0.08 0.7021 -0.24 0.0504 
cg12431087 FOXP1 71355122   61.1 62.0 -0.09 0.6841 -0.20 0.1265 
cg20506347 FOXP1 71355161   59.7 63.6 -0.09 0.6841 -0.20 0.1265 
cg22888463 EIF4E3 71779016   12.8 12.4 -0.17 0.2003 0.04 0.8922 
cg13026730 EIF4E3 71804139 Island 16.1 18.2 0.08 0.7021 -0.20 0.1265 
cg04087740 EIF4E3 71804142 Island 17.4 17.4 0.07 0.7233 -0.11 0.5426 
cg13026730 GPR27 71804139 Island 16.1 18.2 -0.30 0.0017 -0.38 0.0002 
cg04087740 GPR27 71804142 Island 17.4 17.4 -0.31 0.0012 -0.38 0.0003 
cg09655952 PROK2 71833631 N_Shore 28.2 30.6 -0.06 0.7233 -0.15 0.3256 
cg01025398 PROK2 71833878 N_Shore 88.6 95.9 0.07 0.7233 -0.08 0.7599 
cg15798455 PROK2 71833907 N_Shore 40.9 47.9 0.11 0.4965 -0.13 0.4098 
cg19388776 PROK2 71835112 S_Shore 73.8 77.7 0.07 0.7233 -0.01 0.9787 
cg05523500 PPP4R2 73046033 Island 20.8 23.1 0.08 0.7070 0.16 0.2779 
cg25865467 PDZRN3 73673231 Island 61.1 75.2 -0.18 0.1468 -0.23 0.0675 
cg20132590 PDZRN3 73673893 Island 89.3 91.7 -0.14 0.3624 -0.08 0.7355 
cg11148130 PDZRN3 73674068 Island 63.8 68.6 -0.13 0.4092 -0.13 0.4098 
cg26055770 PDZRN3 73674070 Island 67.1 70.2 -0.13 0.4092 -0.11 0.5719 
cg25486757 PDZRN3 73674074 Island 65.8 66.9 -0.16 0.2265 -0.13 0.4370 
cg08141424 PDZRN3 73674087 Island 65.1 68.6 -0.17 0.1882 -0.16 0.2994 
cg10111115 PDZRN3 73674146 Island 61.7 59.5 -0.15 0.2995 -0.07 0.7728 
cg05502701 PDZRN3 73674160 Island 93.3 90.9 -0.19 0.1411 -0.15 0.3474 
cg24353443 PDZRN3 73674166 Island 92.6 96.7 -0.21 0.0834 -0.20 0.1265 
cg14473924 PDZRN3 73674170 Island 73.2 74.4 -0.23 0.0375 -0.23 0.0675 
cg23489627 PDZRN3 73674339 Island 53.7 52.9 -0.24 0.0289 -0.18 0.2034 
cg13688769 PDZRN3 73674363 Island 65.8 65.3 -0.21 0.0834 -0.15 0.3256 
cg21751983 PDZRN3 73674433 S_Shore 76.5 92.6 -0.16 0.2385 -0.13 0.4098 
cg23822879 PDZRN3 73674591 S_Shore 43.0 48.8 -0.20 0.0834 -0.20 0.1265 
cg03869608 PDZRN3 73674656 S_Shore 62.4 73.6 -0.20 0.0834 -0.20 0.1265 
cg14753334 PDZRN3 73674702 S_Shore 85.2 95.0 -0.24 0.0289 -0.21 0.0975 
cg27409478 ZNF717 75834335 Island 83.2 84.3 -0.53 0.0000 -0.44 0.0000 
cg02621032 ZNF717 75834525 Island 77.9 76.0 -0.46 0.0000 -0.36 0.0005 
cg25964040 ZNF717 75834703 Island 47.0 43.0 -0.08 0.7021 0.10 0.6421 
cg16718624 ROBO2 77089518 S_Shore 81.2 89.3 -0.21 0.0739 -0.20 0.1265 
cg11980129 ROBO1 79815639 Island 88.6 94.2 -0.03 0.8829 -0.09 0.7162 
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cg04562217 ROBO1 79815718 Island 99.3 99.2 -0.01 0.9698 -0.08 0.7622 
cg15325658 ROBO1 79815782 Island 100.0 100.0 0.10 0.6347 0.03 0.9133 
cg21865845 ROBO1 79815848 Island 87.9 88.4 0.08 0.7021 0.12 0.5121 
cg07287167 ROBO1 79816794 S_Shore 84.6 81.0 -0.06 0.7233 -0.14 0.3925 
cg10243398 ROBO1 79816838 S_Shore 95.3 95.9 -0.01 0.9770 -0.08 0.7336 
cg07997035 ROBO1 79816949 S_Shore 92.6 97.5 -0.06 0.7233 -0.04 0.8922 
cg21743712 ROBO1 79817125 S_Shore 70.5 80.2 -0.11 0.5124 -0.06 0.8265 
cg08661007 ROBO1 79817232 S_Shore 81.2 86.8 -0.03 0.8829 0.04 0.9020 
cg18703601 ROBO1 79817278 S_Shore 92.6 95.9 -0.06 0.7260 0.03 0.9142 
cg11630696 ROBO1 79817333 S_Shore 89.3 91.7 -0.08 0.7021 0.07 0.7728 
cg07356753 GBE1 81810745 Island 47.7 68.6 0.17 0.2016 -0.01 0.9791 
cg03147002 CADM2 85007732 N_Shore 68.5 71.1 -0.18 0.1468 0.02 0.9484 
cg15355387 CADM2 85007817 N_Shore 61.1 67.8 -0.08 0.7135 0.02 0.9609 
cg20541723 CADM2 85007894 N_Shore 84.6 89.3 -0.06 0.7260 -0.01 0.9787 
cg06217406 CADM2 85007959 N_Shore 77.9 84.3 -0.08 0.7135 0.01 0.9638 
cg25649680 CADM2 85007992 N_Shore 63.1 66.1 -0.07 0.7233 -0.01 0.9704 
cg24621982 CADM2 85008061 N_Shore 79.9 80.2 -0.08 0.7135 0.06 0.8523 
cg12989890 CADM2 85008105 N_Shore 79.9 83.5 -0.09 0.6841 0.02 0.9498 
cg26113636 CADM2 85008156 N_Shore 99.3 100.0 0.00 0.9909 0.16 0.2779 
cg05152589 CADM2 85008678 Island 89.9 95.0 -0.14 0.3624 0.03 0.9133 
cg22380921 CADM2 85008786 Island 90.6 95.0 -0.14 0.3311 0.10 0.6421 
cg12458207 CADM2 85008991 S_Shore 73.8 78.5 -0.08 0.7021 0.08 0.7599 
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Supplementary Table S3 
  C3orf14 FHIT GPR27 LRIG1 ZNF717 THOC7 PSMD6 ADAMTS9 
Patient Gene dosage Gene expression  Mylation Gene dosage Gene expression  Mylation Gene dosage Gene expression  Mylation Gene dosage Gene expression  Mylation Gene dosage Gene expression  Mylation Gene dosage Gene expression  Mylation Gene dosage Gene expression  Mylation Gene dosage Gene expression  Mylation 
P-002 L 5.89 M L 4.96 NM L 6.64 NM L 7.32 NM L 6.10 M L 10.93 M L 10.39 M L 6.07 M 
P-004 NL 9.09 M NL 5.72 NM NL 7.18 NM NL 7.73 M NL 6.27 NM NL 10.93 NM NL 10.60 NM NL 6.59 M 
P-018 NL 9.90 NM NL 5.25 NM NL 6.49 NM NL 7.66 M NL 6.11 M NL 11.45 M NL 10.92 NM NL 7.26 NM 
P-024 NL 9.35 NM NL 5.16 M NL 6.56 NM NL 7.88 M NL 6.09 M NL 11.79 M NL 10.75 NM NL 6.71 NM 
P-028 NL 9.55 NM NL 5.45 NM NL 6.92 NM NL 8.08 M NL 6.16 M NL 11.41 NM NL 10.95 NM NL 6.18 M 
P-032 L 9.39 NM L 5.20 NM L 6.46 NM L 8.43 NM L 5.39 M L 10.61 M L 10.26 NM L 6.57 NM 
P-053 NL 6.05 M NL 5.38 M NL 6.69 M NL 8.56 NM NL 5.60 M NL 10.68 M NL 10.16 NM NL 7.01 NM 
P-063 NL 8.06 M NL 5.41 NM NL 6.80 M NL 7.12 M NL 5.50 M NL 10.95 NM NL 10.95 NM NL 6.88 M 
P-068 L 7.10 M L 5.03 NM L 6.44 NM L 7.72 NM L 6.10 NM L 10.56 NM L 10.16 M L 6.64 M 
P-072 NL 6.33 M NL 5.49 NM NL 6.38 M NL 8.21 M NL 5.43 M NL 11.26 NM NL 10.87 NM NL 6.20 M 
P-074 L 6.59 M L 5.21 M L 6.55 NM L 6.71 M L 5.25 M L 11.13 M L 10.48 M L 6.06 NM 
P-080 L 8.67 NM L 5.39 NM L 6.52 NM L 7.54 NM L 5.81 M L 10.63 M L 10.25 M L 6.83 NM 
P-083 NL 7.61 M NL 5.65 NM NL 6.64 NM NL 9.12 M NL 5.55 M NL 10.86 NM NL 10.72 NM NL 6.70 NM 
P-084 L 6.52 M L 5.36 NM L 6.51 NM L 8.30 M L 5.52 M L 10.35 NM L 10.13 NM L 6.15 M 
P-087 NL 8.74 NM NL 5.41 NM NL 6.67 NM NL 8.22 M NL 5.78 M NL 10.89 NM NL 10.32 M NL 6.26 M 
P-091 NL 6.38 M NL 5.41 NM NL 6.49 NM NL 8.83 NM NL 6.23 M NL 11.32 NM NL 11.09 NM NL 6.40 M 
P-115 L 6.32 M L 5.72 NM L 6.91 NM L 7.60 M L 5.24 M L 10.67 M L 10.00 NM L 6.10 NM 
P-120 L 6.56 M L 5.09 NM L 6.39 NM L 7.99 NM L 5.87 M L 10.58 M L 10.14 M L 6.07 NM 
P-124 NL 7.83 M NL 5.29 NM NL 6.34 M NL 9.02 M NL 5.93 M NL 11.03 NM NL 10.58 NM NL 5.95 M 
P-133 L 8.32 M L 5.44 NM L 6.54 NM L 8.35 NM L 5.43 M L 10.86 NM L 9.89 M L 6.23 M 
P-142 NL 9.52 NM NL 5.50 NM NL 6.45 NM NL 8.37 NM NL 5.92 NM NL 11.42 M NL 11.00 NM NL 6.73 M 
P-151 NL 9.01 M NL 5.17 NM NL 6.56 NM NL 8.30 M NL 5.84 M NL 11.00 M NL 10.55 M NL 7.23 NM 
P-169 NL 8.40 M NL 5.59 NM NL 7.00 NM NL 8.37 M NL 5.20 M NL 11.55 NM NL 10.49 M NL 5.88 M 
P-177 NL 9.74 NM NL 5.18 M NL 6.82 NM NL 7.60 M NL 5.92 M NL 11.65 M NL 11.28 NM NL 6.70 NM 
P-182 L 8.54 M L 5.33 NM L 6.43 M L 6.48 M L 6.37 M L 11.57 M L 11.01 NM L 6.59 M 
P-188 NL 10.23 NM NL 5.19 M NL 6.73 NM NL 6.85 M NL 6.58 M NL 11.48 M NL 11.18 M NL 7.32 M 
P-190 L 7.36 M L 5.52 NM L 6.74 NM L 7.09 M L 5.72 M L 10.79 NM L 10.61 NM L 7.15 M 
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P-191 L 9.84 NM L 5.33 NM L 6.48 M L 7.42 M L 5.69 M L 10.99 NM L 10.52 M L 6.94 M 
P-192 L 9.67 M L 5.49 NM L 6.41 NM L 7.45 M L 6.44 M L 11.34 M L 10.81 NM L 6.70 NM 
P-193 L 9.27 M L 5.36 NM L 6.72 NM L 8.13 M L 5.54 M L 11.52 M L 10.99 M L 5.88 M 
P-194 NL 8.12 M NL 5.47 NM NL 6.40 M NL 8.47 M NL 5.68 M NL 11.25 M NL 10.86 NM NL 6.21 M 
P-196 L 8.03 NM L 5.53 M L 6.35 M L 9.00 NM L 5.41 M L 10.97 M L 10.18 M L 6.15 M 
P-198 NL 8.31 M NL 5.19 M NL 6.56 NM NL 7.18 NM NL 6.00 M NL 10.88 M NL 10.43 M NL 6.51 M 
P-202 L 6.78 M L 5.26 NM L 6.80 NM L 6.36 M L 5.33 M L 10.80 NM L 10.29 M L 5.96 M 
P-208 L 6.60 M L 5.35 NM L 6.49 NM L 7.01 M L 5.72 M L 10.91 M L 10.30 NM L 5.51 M 
P-210 NL 10.42 NM NL 5.59 NM NL 6.75 NM NL 8.62 NM NL 6.06 M NL 11.08 NM NL 10.69 M NL 7.11 M 
P-213 NL 6.39 M NL 5.28 NM NL 6.44 NM NL 7.59 M NL 5.58 M NL 10.72 M NL 10.41 NM NL 5.95 M 
P-215 L 9.09 NM NL 5.78 NM L 6.69 NM L 8.03 M L 5.60 M L 10.74 M L 10.06 NM L 5.84 M 
 
 
